1711P Real-word data challenging the treatment paradigm in metastatic renal cancer: Time to separate IMDC intermediate / poor risk groups?
In the current landscape IMDC prognostic group has been used as a surrogate for treatment choices in 1st line metastatic renal cell carcinoma (mRCC) in clinical trials. This has resulted in distinction between IMDC intermediate & poor risk (IR/PR) group compared to IMDC favourable risk (FR) group wherein, IR/PR IMDC groups get analysed as one treatment group. With clinical equipoise with IOTKI and IOIO in IR/PR group, we have dissected outcomes of 1st line systemic anticancer therapy (SACT) in mRCC by IMDC groups.
Authors
- Ricky Frazer (ORCID: https://orcid.org/0009-0002-0509-1506)
- Amit K. Bahl (ORCID: https://orcid.org/0000-0002-8525-0310)
- D. Lee
- Claire Dyke (ORCID: https://orcid.org/0009-0004-3405-0177)
- John McGrane (ORCID: https://orcid.org/0000-0001-9371-3250)
- T. Geldart (ORCID: https://orcid.org/0000-0001-6413-5789)
- José Carlos Tapia (ORCID: https://orcid.org/0000-0001-6545-8862)
- Jahangeer Malik
- G. J. Meléndez‐Torres (ORCID: https://orcid.org/0000-0002-9823-4790)
- Niall Moon (ORCID: https://orcid.org/0000-0002-3756-9298)
- Dominique Parslow
- Amarnath Challapalli (ORCID: https://orcid.org/0000-0002-3683-9583)
- Cillian T. Forde (ORCID: https://orcid.org/0000-0003-2017-2056)
- Natalie Charnley
- Mark Tuthill
- Priyamvada Roy (ORCID: https://orcid.org/0000-0001-9139-134X)
- Samina Alam
- X-Y. Jiang
- E.C.E. Jones
- W.M. Mohamed
Institutions
- Belfast Health and Social Care Trust (GB)
- Lancashire Teaching Hospitals NHS Foundation Trust (GB)
- NHS Lothian (GB)
- Imperial College Healthcare NHS Trust (GB)
- University of Exeter (GB)
- Velindre NHS Trust (GB)
- Royal Cornwall Hospital Trust (GB)
- Singleton Hospital (GB)
- Poole Hospital (GB)
- Southampton General Hospital (GB)
- At Bristol (GB)
- Newcastle upon Tyne Hospitals NHS Foundation Trust (GB)
- Torbay Hospital (GB)
- Freeman Hospital (GB)
- Charing Cross Hospital (GB)
- Mount Vernon Cancer Centre (GB)
- NIHR Bristol Biomedical Research Centre (GB)
- National Health Service Wales (GB)
- Velindre Cancer Centre (GB)
- Royal Preston Hospital (GB)
- Plymouth Hospital (GB)
- University Hospitals Plymouth NHS Trust (GB)
Publication Details
- Journal
- Annals of Oncology
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1016/j.annonc.2024.08.1804
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00